Apyx Medical Corporation
Price Action
Technical Summary
CONSOLIDATINGApyx Medical Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 56), indicating performance broadly in line with the market. Earnings growth of 74% provides fundamental context to the price action. However, RSI is deeply oversold at 22, suggesting potential for a mean-reversion bounce.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.63 | -19.48% | BELOW |
| 50 SMA | $3.60 | -18.97% | BELOW |
| 100 SMA | $3.70 | -21.09% | BELOW |
| 150 SMA | $3.62 | -19.23% | BELOW |
| 200 SMA | $3.23 | -9.70% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is APYX in an uptrend right now?
APYX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is APYX overbought or oversold?
APYX's RSI (14) is 22. The stock is oversold (RSI < 30), which could indicate a bounce opportunity.
Is APYX outperforming the market?
APYX has a Relative Strength (RS) Rating of 56 out of 99. APYX is performing about average compared to the market.
Where is APYX in its 52-week range?
APYX is trading at $2.92, which is 65% of its 52-week high ($4.50) and 54% above its 52-week low ($1.08).
How volatile is APYX?
APYX has a Beta of 1.96 and 52-week volatility of 99%. It's more volatile than the S&P 500 - expect bigger swings.